TRIER PHARM ApS: Financial statements 2023
CVR: 31611083
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
TRIER PHARM ApS (CVR 31611083) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -86,365 and a net result of DKK -116,420 compared with DKK 35,907 the year before. Equity in the 2023 report amounted to DKK -547,044.
- Gross Profit
- DKK -86,365
- Profit/Loss
- DKK -116,420
- Equity
- DKK -547,044
- Total Assets
- DKK 278,140
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -86 t. | -116 t. | -547 t. | - |
| 2022 | - | 61 t. | 36 t. | -431 t. | - |
| 2021 | - | 32 t. | 9 t. | -467 t. | - |
| 2020 | - | -35 t. | -56 t. | -476 t. | - |
| 2019 | 528 t. | -24 t. | -40 t. | -420 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
TRIER PHARM ApS has published its annual report for 2022. Gross profit came to DKK 61,044, and the net result was DKK 35,907.
About TRIER PHARM ApS
TRIER PHARM ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2008. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Klaus Trier. The company is owned by KLAUS TRIER HOLDING ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -37,612 and a net result of DKK -67,143 compared with DKK -18,582 the year before. Equity in the 2025 report amounted to DKK -632,769.